Predict your next investment

TEDOR Pharma company logo
HEALTHCARE | Drug Manufacturing / Generics
tedorpharma.com

See what CB Insights has to offer

Stage

Loan | Alive

Total Raised

$1.5M

Last Raised

$1.5M | 1 yr ago

About TEDOR Pharma

TEDOR Pharma is a full-service, end-to-end, contract development and manufacturing company (CDMO) that specializes in solid oral dose, controlled substance formulations. TEDOR's products include immediate and modified release solid oral dose formulations in tablets and capsules, including DEA Scheduled II-V controlled drugs.

TEDOR Pharma Headquarter Location

400 Highland Corporate Drive

Cumberland, Rhode Island, 02864,

United States

401-405-3000

Latest TEDOR Pharma News

Tedor Pharma expanding in Cumberland

Dec 14, 2016

Tedor Pharma expanding in Cumberland By Mary MacDonald Tedor Pharma Inc., a pharmaceutical development and manufacturing company, will double its production capacity this coming year with a multi-million dollar expansion. To continue reading this article, please do one of the following. You can purchase access to this single article, if you prefer. Wednesday, December 14, 2016 4:18 pm By Mary MacDonald Twitter: @MaryF_MacDonald real estate Fane ready to move forward on 43-floor high-rise in Providence (Dec. 8, 2016) CUMBERLAND – Tedor Pharma Inc., a pharmaceutical development and manufacturing company, will double its production capacity this coming year with a multi-million dollar expansion. The project total was not disclosed. The company, which manufactures 12 drugs with U.S. Food and Drug Administration approval, and has more in the development pipeline, has contracted with Shawmut Design and Construction on the work. The construction will add 5,400 square feet of new or renovated space at the existing 40,000 square-foot manufacturing facility at Highland Corporate Park. Shawmut will renovate 3,300 square feet of existing space, and build a 2,100-square-foot addition as part of the work. Tedor also plans to expand its workforce by 20 in 2017, to a total of 80 employees, according to a company news release. The expansion, which broke ground in October, is expected to be completed in May. “This investment is in response to our clients’ demand for large-scale, multi-purpose manufacturing capabilities,” said Carl Wooten, Tedor Pharma CEO and president, in a news release. “The manufacturing addition and investment in several technologies will double our capacity and will allow us to add sought after, high-skilled jobs to the local economy.” Keywords

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

TEDOR Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TEDOR Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.